ArticleJournal of immunology (Baltimore, Md. : 1950)2026
IL-22 synergizes with IL-17 to promote mucosal inflammation and bone loss.
Article in Journal of immunology (Baltimore, Md. : 1950), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Interleukin (IL)-22 mediates immune cell communication with nonhematopoietic cells and was shown to exert protective or destructive effects in different disease contexts. In the oral mucosal disease periodontitis, IL-22 has been associated with increased tissue destruction, although cause-and-effect evidence and the underlying mechanisms are lacking. Here, we showed that endogenous IL-22 was required for experimental periodontitis in mice, whereas local administration of exogenous IL-22 exacerbated periodontal inflammation and bone loss. Importantly, the ability of IL-22 to induce expression of inflammatory cytokines and tissue-degrading metalloproteinases as well as cause bone loss required intact IL-17 function, suggesting a potential cooperation between the two cytokines. As human fibroblasts prominently coexpress IL-22 and IL-17 receptors in the periodontal tissue and play a role in the pathogenesis of periodontitis, we examined them in vitro as potential targets of a destructive IL-22-IL-17 interplay. IL-22 synergized with IL-17 for enhanced nuclear factor κB-mediated inflammatory responses (IL-6, matrix metalloproteinase-1) in a STAT3-dependent manner. Analysis of cytosolic and nuclear extracts revealed that IL-22 enhanced nuclear factor κB p65 phosphorylation and translocation to the nucleus of IL-17-stimulated fibroblasts. In conclusion, our study provides causal evidence for IL-22 involvement in periodontitis and describes a hitherto unknown IL-22-IL-17 synergy in inflammatory bone loss.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.